Global Human Serum Albumin Market Strategic Research Report

Scope of the Report

The global Human Serum Albumin market size is predicted to grow from US$ 6,923 million in 2025 to US$ 10,600 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.

Human Serum Albumin is a water-soluble globular protein produced in the liver. It accounts for 50% of blood plasma proteins. These play a vital role in regulating blood volume and act as transporters for molecules such as few hormones, bile salts, and ions. Albumin is commonly used as blood volumizer in rare diseases, burns, shocks, liver conditions, and other blood loss trauma and surgeries.

The human serum albumin (HSA) market is driven by the increasing prevalence of liver diseases, nephrotic syndrome, and hypoalbuminemia, which require albumin-based therapies. Additionally, HSA is widely used in critical care settings for treating burns, shock, and surgical recovery, boosting its demand. The expanding applications of albumin in biopharmaceuticals, including drug delivery, vaccine formulation, and regenerative medicine, further fuel market growth. Rising healthcare expenditures, improvements in plasma collection infrastructure, and growing demand in emerging markets like China and India contribute to the industry's expansion.

However, the market faces challenges such as limited plasma supply and high production costs, as HSA is primarily derived from human plasma, which is subject to stringent donation regulations. Stringent government policies and safety concerns regarding pathogen transmission also hinder market growth. Additionally, competition from synthetic and recombinant HSA (rHSA) is increasing, though high production costs and market acceptance remain barriers. Overcoming supply chain constraints and advancing rHSA technologies will be crucial for sustaining growth in the global HSA market.

The key global producers of human serum albumin are Grifols, CSL, Takeda, Octapharma, CBPO, Hualan Bio, Kedrio, and Shanghai RAAS, with the top four manufacturers together holding 60% of the market share. The largest producer is CSL with a market share of 21.25%. In terms of consumption level, the market is mainly distributed in North America, Europe and Asia Pacific, with Asia Pacific having the highest market share of 68.63%.

This report presents a comprehensive overview of the global Human Serum Albumin market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 20-25% Concentrations
• 5% Concentrations

Segment by Application

• Therapeutics
• Excipient
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Human Serum Albumin market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Therapeutics, Excipient, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact